KIT and acute myeloid leukemia: Exploring mechanisms of constitutive PI3K/Akt/mTOR activation in AML identified mutations of RTKs (e.g., FLT3-ITD, c-KIT) or GTPases (KRAS, NRAS) as well as autocrine IGF-1/IGF-1R signaling responsible for dysregulation [109,110].